You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
None
One in five adolescents have special healthcare needs; one in 10 face limitations to daily activities due to chronic illness or disability. Taken alongside the ever-changing societal landscape and the multifaceted psychological aspects of adolescence, these statistics underline the need to recognise adolescents and young adults as a distinct patient population with unique healthcare needs. This Monograph addresses this need. Opening with chapters that discuss health inequalities, adolescent psychology and treatment adherence, the book goes on to cover specific respiratory diseases and the requirements of their adolescent subjects. Readers will find this Monograph a useful and interesting insight into adolescent health.
Recent years have witnessed key developments in the diagnosis and treatment of tuberculosis. Alongside this, and running in direct opposition to this progress, was the COVID-19 pandemic, which had an unprecedented detrimental effect on tuberculosis control and the achievement of targets set by the End TB Strategy. This timely and important Monograph provides a crucial update on recent changes, developments and setbacks in the field, and calls for a re-commitment to the achievement of the End TB Strategy and Sustainable Development Goals. Written by authors from across the world, the Monograph covers: diagnosis; advances in treatment; prevention; and tuberculosis control challenges in different populations and contexts.
The story of COVID-19 now seems so familiar: from the first reported case of a new respiratory infection in China in December 2019, to a pandemic that rapidly changed the world. Respiratory clinicians and scientists were at the forefront of delivering healthcare for people with COVID-19, leading efforts to understand this novel virus and disease, and developing and testing strategies to better prevent and treat it. These endeavours extended not only to the acute illness, but also to understanding the longer-term consequences. The pace of knowledge acquisition was rapid but is now maturing. This Monograph therefore provides a timely and valuable state-of-the-art summary for clinicians and scientists on our understanding of this virus and its consequences to date. It is essential reading for all those involved in the care of people who are or who have been affected by COVID-19.
Diagnosing rare diseases can be challenging, and treating these conditions is complex because of their often quite specific needs and treatment options. To address this, the European Respiratory Society (ERS) has published Rare Diseases of the Respiratory System. Structured into thematic sections, the book covers: the identification of rare diseases of the respiratory system and their differential diagnosis; rare diseases of the lung interstitium; rare diseases of the airways or alveoli; and rare pulmonary vascular diseases. The Guest Editors and authors belong to and/or support the vision and mission of the European Reference Network for Rare Diseases of the Respiratory System (ERN-LUNG), which offers expert support to both patients and professionals. As such, this comprehensive book will prove an excellent resource for healthcare professionals, researchers and students interested in rare diseases of the respiratory system.
In the last 10 years, the use of clinical exercise testing in respiratory medicine has grown significantly and, if used in the appropriate context, it has been demonstrated to provide clinically useful and relevant information. However, as its implementation and interpretation can be complicated, it should be used alongside previous medical evaluation (including medical history, physical examination and other appropriate complementary tests) and should be interpreted with the results of these additional tests in mind. This timely ERS Monograph aims to provide a comprehensive update on the contemporary uses of exercise testing to answer clinically relevant questions in respiratory medicine. The book covers: equipment and measurements; exercise testing in adults and children; cardiac diseases; interstitial lung disease; pulmonary vascular disease; chronic obstructive pulmonary disease; pre-surgical testing; and much more.
The coexistence of lung disease and cancer in the same person is a frequent occurrence. Evidence suggests that this coexistence sometimes goes beyond chance; in fact, both disease types are associated and the presence of one can be a risk factor or a protective factor for the other. In this Monograph, the Guest Editors bring together renowned clinical and scientific experts to provide an exhaustive review of the bidirectional relationship between respiratory diseases and cancer (not just lung cancer). The chapters: explore the common causal pathways of cancer and lung disease; consider the diseases from an epidemiological, clinical and therapeutic point of view; and discuss the many ways in which they interact to influence patient management. The result is a book that will generate a better understanding of this relationship, giving rise to a greater awareness of the possible development of lung disease in people with cancer, and of the different types of cancer that are frequently seen in those with lung diseases.
COPD remains a major cause of ill health, disability, healthcare costs and premature mortality. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results. This Monograph provides an up-to-date overview of what is happening in this exciting field, both at a basic and a clinical level. Beginning, crucially, with the patient’s perspective, the chapters that follow consider the best way to define COPD, changes in the disease’s incidence and prevalence, and offer new insights into the role of the microbiome in COPD, advances in imaging and treatment options, both pharmacological and non-pharmacological. Taken together, these chapters are an important contribution to the Monograph series and the COPD field in general.
In May 2023, WHO declared that COVID-19 was no longer a public health emergency of international concern. In 2024, COVID-19 certainly has not gone away, but we can now take a more reflective look at the pandemic. This issue of the ERS Monograph does just that, bringing together a truly international group of experts, as befits a global illness, to consider areas such as: long-term sequelae in airway disease, interstitial lung disease, and in the immunocompromised; therapeutics in the community, in hospital and in the intensive care unit; and the pathophysiology and management of long COVID. The Guest Editors also consider the impact of COVID-19 on clinical research and scientific publishing, as well as looking to the future, considering what can be learnt from the pandemic.
Respiratory care is undergoing a period of major change as it cautiously begins to embrace digital transformation. Catalysed by the need for remote consultation in the pandemic, time-honoured approaches to delivering care are now being challenged by technology-based initiatives. This Monograph deftly guides the reader through the potential benefits and pitfalls of such change, breaking the discussion down into three areas: technological opportunities and regulatory challenges ; social benefits, challenges and implications; exemplars of digital healthcare. Each chapter reviews contemporary literature and considers not ‘if’ but ‘how’ a digital respiratory future can provide optimal care. The result is an authoritative, balanced guide to developing digital respiratory health.